Invasive lobular breast cancer and its variants: how special are they for systemic therapy decisions?

Abstract : The WHO classification of breast tumors distinguishes, besides invasive breast cancer 'of no special type' (former invasive ductal carcinoma, representing 60-70% of all breast cancers), 30 special types, of which invasive lobular carcinoma (ILC) is the most common (5-15%). We review the literature on (i) the specificity and heterogeneity of ILC biology as documented by various analytical techniques, including the results of molecular testing for risk of recurrence; (ii) the impact of lobular histology on prediction of prognosis and effect of systemic therapies in patients. Though it is generally admitted that ILC has a better prognosis than IDC, is endocrine responsive, and responds poorly to chemotherapy, currently available data do not unanimously support these assumptions. This review demonstrates some lack of specific data and a need for improving clinical research design to allow oncologists to make informed systemic therapy decisions in patients with ILC. Importantly, future studies should compare various endpoints in ILC breast cancer patients among the group of hormonosensitive breast cancer.
Type de document :
Article dans une revue
Liste complète des métadonnées

https://hal.umontpellier.fr/hal-02181369
Contributeur : Cécile Nowak <>
Soumis le : vendredi 12 juillet 2019 - 09:19:28
Dernière modification le : mercredi 7 août 2019 - 13:52:06

Identifiants

Collections

Citation

S. Guiu, A. Wolfer, William Jacot, P. Fumoleau, G. Romieu, et al.. Invasive lobular breast cancer and its variants: how special are they for systemic therapy decisions?. Critical Reviews in Oncology/Hematology, Elsevier, 2014, 92, pp.235--57. ⟨10.1016/j.critrevonc.2014.07.003⟩. ⟨hal-02181369⟩

Partager

Métriques

Consultations de la notice

15